HF/Transplantation News

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.

Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have pre-existing cardiovascular disease, according to results of a retrospective study.

Weight gain after a breast cancer diagnosis elevated a person’s risk for heart failure, according to results of an observational study in the Republic of Korea.

The health benefits of time-restricted eating go beyond weight loss and may be most prominent in patients already with cardiometabolic syndrome at baseline, a speaker reported.

Among adults with osteoporosis on dialysis, use of denosumab significantly lowered fracture risk compared with bisphosphonate use, but cardiovascular risk was increased, according to study data.

The American College of Cardiology recently issued an expert consensus document outlining a novel staging system and decision pathway for the diagnosis, treatment and longitudinal follow-up of patients with myocarditis.

Women with heart failure with preserved ejection fraction have sex-specific differences in presentation, diagnosis and treatment responses, highlighting the importance of proper diagnoses and guideline-directed medical therapy initiation.

Genetically predicted major depression may present in women, but not men, with increased risk for arrhythmia disorders, coronary artery disease and heart failure, and risk may vary based on menopausal status, researchers reported.

Johnson & Johnson MedTech announced the FDA has approved an expanded indication and granted premarket approval for its heart pumps to be used to treat pediatric patients with symptomatic acute decompensated HF and cardiogenic shock.